Inpharma Weekly

, Volume 1122, Issue 1, pp 9–10 | Cite as

Selective COX-2 inhibitors gather speed

  • Amanda Cameron
Newsletter Article


Selective inhibitors of cyclo-oxygenase type 2 (COX-2) continue to tantalise rheumatologists with the promise of delivering the same anti-inflammatory and analgesic effects as those of conventional NSAIDs, without the adverse gastrointestinal (GI) effects commonly seen with these drugs. The results of clinical trials of two COX-2 inhibitors, Searle’s celecoxib and Merck’s MK 966, were presented at the recent National Scientific Meeting of the American College of Rheumatology [ Washington DC, US; November 1997 ]. These results add to the growing body of evidence supporting the efficacy of COX-2 inhibitors in reducing pain and inflammation to a similar degree as conventional NSAIDs. However, an improved long-term tolerability profile remains to be demonstrated over the traditional NSAIDs.


Celecoxib Naproxen Traditional NSAID Conventional NSAID Naproxen 500mg 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Copyright information

© Adis International Ltd 1998

Authors and Affiliations

  • Amanda Cameron

There are no affiliations available

Personalised recommendations